Hung ju­ry vote leaves FDA with a dif­fi­cult de­ci­sion on Durec­t's non-opi­oid painkiller

6 years ago
R&D
FDA+

Bio­Marin ex­ecs dis­cuss some eye-pop­ping num­bers for the price of val­rox — but haven't we heard this be­fore?

6 years ago
R&D

#JPM20: Five years af­ter first PC­SK9, No­var­tis goes for win as Sanofi moves on, Am­gen sal­vages what's left

6 years ago
R&D

Mayo Clin­ic launch­es clin­i­cal an­a­lyt­ics plat­form with nfer­ence; WuXi buys Ger­man plant from Bay­er

6 years ago
News Briefing

The FDA: Faster, but not nec­es­sar­i­ly bet­ter. And that could threat­en the agen­cy's brand

6 years ago
R&D
FDA+

#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of ...

6 years ago
People
R&D

Fra­zier clos­es 12th fund in 30 years, with $617M to bet on cell/gene ther­a­py, Big Phar­ma spin­offs and more

6 years ago
Financing

Neon Ther­a­peu­tics makes one last re­treat, sell­ing it­self cheap in a bar­gain base­ment M&A deal

6 years ago
Deals
R&D

Bio­phar­ma's Chi­na plan gets a boost from patent pro­tec­tions sealed in now of­fi­cial trade deal

6 years ago
China
FDA+

Gov­ern­ment spend­ing bill tweak means 3 more NDAs will be­come BLAs, FDA says

6 years ago
FDA+

GSK, Pfiz­er con­tra­dict on the fu­ture of con­sumer health JV — re­port

6 years ago
Pharma

#JPM20: Af­ter a year of NASH col­laps­es, all eyes on two biotechs

6 years ago
R&D
In Focus

Video Re­play: End­points at #JPM20 — news­mak­ers on deal­mak­ing, pric­ing and man­u­fac­tur­ing

6 years ago
Publisher's note

Cel­gene ex­ec jumps to head blue­bird bio ops in Eu­rope, where its $1.8M gene ther­a­py Zyn­te­glo is now avail­able

6 years ago
People

FDA grants pri­or­i­ty re­view for Rubra­ca; Arpeg­gio snags $3.2M in seed fi­nanc­ing

6 years ago
News Briefing

FDA staff high­lights neu­ro­log­i­cal safe­ty con­cerns with Durec­t's pain drug

6 years ago
FDA+

Take­da hops on­to $61M round for CRISPR play­er syn­the­siz­ing Cas9 al­ter­na­tives

6 years ago
Financing
Startups

War­ren and Klobuchar say they can low­er drug prices with­out Con­gress’ help

6 years ago
People
Pharma

Gala­pa­gos beefs up its fi­bro­sis pipeline, las­so­ing 4 more pro­grams and tak­ing a stake in small Cana­di­an part­ner

6 years ago
Deals

UK's NICE is­n't con­vinced by Mer­ck­'s Keytru­da in head and neck can­cer

6 years ago
FDA+

Nek­tar aban­dons opi­oid drug af­ter a unan­i­mous 27-0 re­buff from FDA ad­comm

6 years ago
R&D

UPMC ven­ture arm ear­marks $1B in­vest­ment in life sci­ences

6 years ago
Financing

Ipsen re­cruits Steven Hilde­mann as CMO; Eli Lil­ly of­fers two more low-cost in­sulin op­tions

6 years ago
News Briefing

Four years af­ter 'moon­shot' launch, Patrick Soon-Sh­iong has a big re­veal: a sin­gle pa­tient

6 years ago
R&D
First page Previous page 862863864865866867868 Next page Last page
A service from the Financial Times